|
Physiomics PLC on Friday said it has won a contract with a new client in the UK. The Oxfordshire, England-based mathematical modelling company said the project will involve the application of pharmacokinetic modelling techniques, using phase one data to inform the phase two study of a molecule designed to treat rheumatoid arthritis. It said the project is valued at £67,500 and is scheduled to complete within the next three months. Physiomics said it has also struck a master service agreement with the client on broad commercial terms for future potential projects. Chief Executive Officer Peter Sargent said: ‘We’re delighted to have been selected to support the clinical development of this important programme. ‘This contract award not only represents a new client relationship - the third new client in two months - but also is a reflection of our strategy to broaden our services into new therapeutic areas, being our first project in rheumatoid arthritis.’ He continued: ‘In addition, this project is a great opportunity for us to demonstrate our capabilities in supporting programmes at a more advanced stage of development and is well suited to our expertise. ‘We look forward to contributing meaningful insights that can help accelerate and optimise this molecules progress through the clinic.’ Shares in Physiomics were down 4.3% at 0.42 pence in London early on Friday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
